Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.

Nasopharyngeal carcinoma PI3K/AKT/mTOR miRNAs

Journal

Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860

Informations de publication

Date de publication:
26 Jul 2022
Historique:
received: 16 04 2022
accepted: 06 07 2022
entrez: 26 7 2022
pubmed: 27 7 2022
medline: 27 7 2022
Statut: epublish

Résumé

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumours of the head and neck in Southeast Asia and southern China. The Phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway is involved in processes related to tumour initiation/progression, such as proliferation, apoptosis, metastasis, and drug resistance, and is closely related to the clinicopathological features of NPC. In addition, key genes involved in the PI3K/AKT/mTOR signalling pathway undergo many changes in NPC. More interestingly, a growing body of evidence suggests an interaction between this signalling pathway and microRNAs (miRNAs), a class of small noncoding RNAs. Therefore, in this review, we discuss the interactions between key components of the PI3K/AKT/mTOR signalling pathway and various miRNAs and their importance in NPC pathology and explore potential diagnostic biomarkers and therapeutic targets.

Identifiants

pubmed: 35883139
doi: 10.1186/s40364-022-00397-x
pii: 10.1186/s40364-022-00397-x
pmc: PMC9327212
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

52

Informations de copyright

© 2022. The Author(s).

Références

Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
J Pathol. 2022 Apr;256(4):402-413
pubmed: 34919276
Clin Cancer Res. 2016 Apr 15;22(8):2009-19
pubmed: 26589432
Anticancer Drugs. 2020 Oct;31(9):932-941
pubmed: 32282369
World J Surg Oncol. 2020 Feb 3;18(1):29
pubmed: 32013999
Mol Cell Biol. 2004 Jan;24(1):200-16
pubmed: 14673156
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
pubmed: 16166262
Pharmacol Ther. 2014 May;142(2):164-75
pubmed: 24333502
Int J Mol Sci. 2021 Jun 30;22(13):
pubmed: 34209172
Oncogene. 2015 Apr 23;34(17):2156-66
pubmed: 25347742
Life Sci. 2020 Aug 1;254:117672
pubmed: 32304760
Cell Death Dis. 2020 Jul 2;11(7):509
pubmed: 32641685
Cell Death Dis. 2018 Mar 12;9(3):393
pubmed: 29531214
Med Sci Monit Basic Res. 2020 May 25;26:e923431
pubmed: 32448862
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Genes (Basel). 2020 Aug 04;11(8):
pubmed: 32759652
Cell Mol Biol Lett. 2020 Nov 3;25(1):49
pubmed: 33292168
Dis Markers. 2016;2016:7648215
pubmed: 27667893
Nat Commun. 2016 Apr 20;7:11309
pubmed: 27095304
Trends Biochem Sci. 2013 Dec;38(12):612-20
pubmed: 24239264
Am J Cancer Res. 2015 Apr 15;5(5):1602-9
pubmed: 26175931
Biomed Pharmacother. 2016 Feb;77:37-44
pubmed: 26796263
Mol Cancer Ther. 2015 Feb;14(2):429-39
pubmed: 25504751
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
J Cancer. 2020 Apr 6;11(13):3976-3985
pubmed: 32328201
Nat Rev Cancer. 2005 Sep;5(9):726-34
pubmed: 16148885
Head Neck. 2022 Jul;44(7):1576-1587
pubmed: 35394102
Cancer Lett. 2014 Feb 1;343(1):24-32
pubmed: 24041865
Biochem Biophys Res Commun. 2013 Nov 29;441(4):958-63
pubmed: 24220341
J Oncol. 2021 Dec 17;2021:6060762
pubmed: 34956364
Dev Cell. 2006 Dec;11(6):859-71
pubmed: 17141160
Carcinogenesis. 2013 Feb;34(2):454-63
pubmed: 23125220
Mol Cancer. 2014 Mar 08;13:51
pubmed: 24606633
Nature. 2004 Mar 18;428(6980):332-7
pubmed: 15029198
IUBMB Life. 2021 Apr;73(4):618-642
pubmed: 33476088
Nat Struct Mol Biol. 2012 Jun 05;19(6):586-93
pubmed: 22664986
Oncogene. 2012 Oct 11;31(41):4421-33
pubmed: 22249270
Biosci Rep. 2019 Nov 29;39(11):
pubmed: 31658358
Exp Ther Med. 2022 Feb;23(2):136
pubmed: 35069817
J Clin Lab Anal. 2022 Feb;36(2):e24194
pubmed: 35028969
Arch Physiol Biochem. 2020 Aug 14;:1-6
pubmed: 32795216
Oncotarget. 2016 Mar 22;7(12):13634-50
pubmed: 26872369
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cells. 2020 Mar 18;9(3):
pubmed: 32197467
Braz J Med Biol Res. 2020 Oct 30;53(12):e9740
pubmed: 33146288
J Transl Med. 2022 Jun 8;20(1):264
pubmed: 35676661
Oncotarget. 2016 Jan 19;7(3):3047-58
pubmed: 26655091
Adv Drug Deliv Rev. 2015 Jun 29;87:3-14
pubmed: 25979468
Front Pharmacol. 2018 Dec 11;9:1362
pubmed: 30618730
Oncotarget. 2015 Sep 29;6(29):28341-56
pubmed: 26314966
Genes (Basel). 2021 Nov 21;12(11):
pubmed: 34828441
Front Oncol. 2021 Oct 15;11:720835
pubmed: 34722264
PLoS One. 2013 Oct 23;8(10):e78355
pubmed: 24194922
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Front Pharmacol. 2019 Mar 18;10:253
pubmed: 30936832
Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
pubmed: 20379207
Biochem Pharmacol. 2021 Jul;189:114384
pubmed: 33347867
Oncol Rep. 2018 Apr;39(4):1631-1639
pubmed: 29484437
Biomed Pharmacother. 2021 Jan;133:110986
pubmed: 33166764
J Cell Physiol. 2019 Aug;234(10):17912-17924
pubmed: 30834525
Iran J Basic Med Sci. 2019 May;22(5):541-546
pubmed: 31217935
Cell Mol Biol (Noisy-le-grand). 2020 Oct 31;66(7):44-50
pubmed: 33287921
Med Sci Monit Basic Res. 2019 Feb 18;25:53-62
pubmed: 30773530
Curr Cancer Drug Targets. 2022;22(5):388-403
pubmed: 34970954
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Feb 28;47(2):165-173
pubmed: 35545406
Apoptosis. 2004 Nov;9(6):667-76
pubmed: 15505410
Cell Res. 2014 Jan;24(1):24-41
pubmed: 24366339
Int J Mol Sci. 2020 Dec 26;22(1):
pubmed: 33375317
Biochim Biophys Acta Gen Subj. 2018 Dec;1862(12):2688-2700
pubmed: 30251659
Onco Targets Ther. 2019 Aug 26;12:6917-6925
pubmed: 31692593
Cell Commun Signal. 2014 Oct 11;12:66
pubmed: 25304455
FASEB J. 2019 Nov;33(11):11959-11972
pubmed: 31408612
Crit Rev Oncol Hematol. 2016 Jul;103:1-9
pubmed: 27179594
Clin Cancer Res. 2007 Dec 15;13(24):7421-31
pubmed: 18094426
Front Oncol. 2021 Dec 20;11:738252
pubmed: 34988010
Neoplasma. 2019 Sep;66(5):825-829
pubmed: 31129965
Kaohsiung J Med Sci. 2017 Sep;33(9):427-432
pubmed: 28865599
PLoS One. 2013 Dec 19;8(12):e84486
pubmed: 24367666
Mol Cell Biochem. 2021 Jun;476(6):2317-2335
pubmed: 33582947
Radiat Oncol. 2021 Oct 11;16(1):198
pubmed: 34635145
Int J Mol Sci. 2021 Jun 28;22(13):
pubmed: 34203300
Cancer Sci. 2021 Jun;112(6):2393-2404
pubmed: 33728743
Gene. 2019 Aug 20;710:103-113
pubmed: 31158447
Cancers (Basel). 2019 Jul 05;11(7):
pubmed: 31284467
Ther Adv Med Oncol. 2020 Aug 27;12:1758835920937890
pubmed: 32922520
Int J Mol Sci. 2021 Sep 11;22(18):
pubmed: 34575999
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
PLoS One. 2015 Apr 23;10(4):e0119015
pubmed: 25906254
Cancers (Basel). 2021 Aug 29;13(17):
pubmed: 34503179
Anticancer Drugs. 2020 Apr;31(4):385-393
pubmed: 31913198
Semin Cancer Biol. 2012 Apr;22(2):166-72
pubmed: 22178394
J Exp Clin Cancer Res. 2016 Dec 5;35(1):188
pubmed: 27919278
Cell Mol Biol (Noisy-le-grand). 2018 Oct 30;64(13):21-25
pubmed: 30403591
Cancer Cell Int. 2017 Mar 1;17:32
pubmed: 28265202
Front Oncol. 2020 Feb 05;10:104
pubmed: 32117754
Front Cell Dev Biol. 2020 Apr 16;8:232
pubmed: 32373608
Drug Discov Today. 2019 Oct;24(10):2086-2095
pubmed: 31173912
Biomolecules. 2019 Apr 17;9(4):
pubmed: 30999672
Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11096-11104
pubmed: 33215426
Front Oncol. 2021 Feb 25;11:605988
pubmed: 33718157
Diagnostics (Basel). 2020 Aug 19;10(9):
pubmed: 32825179
PLoS One. 2014 Aug 28;9(8):e106098
pubmed: 25165983
Semin Cancer Biol. 2019 Dec;59:125-132
pubmed: 31323288
Cancer Biomark. 2018;23(1):107-123
pubmed: 29991129
Mol Med Rep. 2018 Jun;17(6):8244-8252
pubmed: 29693120
Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2321-2327
pubmed: 29762835
J Exp Clin Cancer Res. 2019 Apr 8;38(1):151
pubmed: 30961650
PLoS One. 2014 Jan 31;9(1):e87767
pubmed: 24498188
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7935-7942
pubmed: 31599418
Nat Commun. 2015 Jul 02;6:7353
pubmed: 26135619
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Cancer Treat Rev. 2019 Sep;79:101890
pubmed: 31470314
BMC Cancer. 2019 Jan 24;19(1):104
pubmed: 30678643
Oncol Rep. 2020 Apr;43(4):1169-1186
pubmed: 32323781
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1524-1532
pubmed: 31919282
Am J Cancer Res. 2021 Dec 15;11(12):5833-5855
pubmed: 35018228
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
J Nanobiotechnology. 2022 Jun 14;20(1):279
pubmed: 35701788
Semin Cancer Biol. 2019 Dec;59:147-160
pubmed: 31128298
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4940-4947
pubmed: 31210329
J Cell Physiol. 2020 May;235(5):4146-4152
pubmed: 31663122
BMC Cancer. 2016 Mar 15;16:218
pubmed: 26975503
Biosci Rep. 2019 Sep 13;39(9):
pubmed: 31471531
Cell. 2009 May 29;137(5):873-86
pubmed: 19446321
Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):12867-12877
pubmed: 33378037
Lancet Oncol. 2015 Jun;16(6):645-55
pubmed: 25957714
Nat Commun. 2018 Nov 27;9(1):5009
pubmed: 30479336
Biomed Pharmacother. 2018 Sep;105:633-644
pubmed: 29898430
Biomark Res. 2022 May 3;10(1):28
pubmed: 35505392
Clin Exp Med. 2022 Jan 15;:
pubmed: 35031885
Acta Pharmacol Sin. 2012 Aug;33(8):981-2
pubmed: 22751478
Biochem Biophys Res Commun. 2014 Feb 7;444(2):199-204
pubmed: 24440701
Cell Death Dis. 2019 Feb 21;10(3):176
pubmed: 30792382
Genes Genomics. 2020 Aug;42(8):971-978
pubmed: 32648233
Front Oncol. 2022 Mar 24;12:819128
pubmed: 35402264
Mol Cell. 2015 Feb 19;57(4):708-720
pubmed: 25639470
J Clin Oncol. 2015 Oct 10;33(29):3346-55
pubmed: 26351340
Cell Death Dis. 2019 Apr 3;10(4):305
pubmed: 30944308
Life Sci. 2021 Nov 15;285:119984
pubmed: 34592229
Int J Biol Sci. 2022 Feb 21;18(5):1878-1895
pubmed: 35342334
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819892251
pubmed: 31984860
J Biol Chem. 2013 Mar 1;288(9):6034-44
pubmed: 23300087
J Ovarian Res. 2019 Dec 9;12(1):121
pubmed: 31815639
Expert Rev Proteomics. 2019 Jun;16(6):475-485
pubmed: 31056975
J Cell Biochem. 2019 Jun;120(6):10186-10194
pubmed: 30582216
Cancer Biol Ther. 2017 Sep 2;18(9):681-693
pubmed: 28799829
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Signal Transduct Target Ther. 2020 Oct 23;5(1):245
pubmed: 33093441
Life Sci. 2020 Dec 1;262:118480
pubmed: 32980391
Int J Mol Med. 2013 Apr;31(4):904-12
pubmed: 23426850
Cell Cycle. 2012 Feb 15;11(4):785-96
pubmed: 22374676
Oncol Res. 2018 Apr 10;26(3):363-372
pubmed: 28560951
Int J Biochem Cell Biol. 2021 Dec;141:106092
pubmed: 34626803
Front Immunol. 2021 Sep 09;12:680955
pubmed: 34566954
Am J Cancer Res. 2021 Jun 15;11(6):2508-2520
pubmed: 34249413

Auteurs

Hai-Long Li (HL)

Key Laboratory of Cancer Cellular and Molecular Pathology in Hunan Province, Cancer Research Institute of Medical College, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, P.R. China.

Nian-Hua Deng (NH)

Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, P.R. China.

Xiu-Sheng He (XS)

Key Laboratory of Cancer Cellular and Molecular Pathology in Hunan Province, Cancer Research Institute of Medical College, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, P.R. China. hxs202009@163.com.

Yue-Hua Li (YH)

Department of Medical Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, 421001, Hengyang, P.R. China. liyuehua2020@stu.usc.edu.cn.

Classifications MeSH